Quest Diagnostics Incorporated $DGX Stock: SVB Wealth LLC Lowers Stake

SVB Wealth LLC trimmed its position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 30.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,271 shares of the medical research company’s stock after selling 3,559 shares during the quarter. SVB Wealth LLC’s holdings in Quest Diagnostics were worth $1,928,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Choreo LLC lifted its holdings in shares of Quest Diagnostics by 2.4% in the 3rd quarter. Choreo LLC now owns 2,215 shares of the medical research company’s stock worth $516,000 after acquiring an additional 52 shares during the last quarter. Kingswood Wealth Advisors LLC grew its holdings in Quest Diagnostics by 1.4% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 3,878 shares of the medical research company’s stock valued at $904,000 after purchasing an additional 55 shares during the last quarter. Concurrent Investment Advisors LLC raised its position in Quest Diagnostics by 1.2% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 5,183 shares of the medical research company’s stock worth $1,099,000 after purchasing an additional 62 shares during the period. SBI Securities Co. Ltd. raised its position in Quest Diagnostics by 17.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 441 shares of the medical research company’s stock worth $112,000 after purchasing an additional 67 shares during the period. Finally, North Dakota State Investment Board raised its position in Quest Diagnostics by 2.1% in the 3rd quarter. North Dakota State Investment Board now owns 3,382 shares of the medical research company’s stock worth $788,000 after purchasing an additional 68 shares during the period. Institutional investors own 88.06% of the company’s stock.

Insider Activity

In related news, EVP Catherine T. Doherty sold 22,105 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $248.02, for a total value of $5,482,482.10. Following the completion of the sale, the executive vice president directly owned 71,949 shares of the company’s stock, valued at $17,844,790.98. This represents a 23.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary M. Pfeiffer sold 1,203 shares of the stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $243.00, for a total transaction of $292,329.00. Following the transaction, the director owned 29,802 shares in the company, valued at approximately $7,241,886. The trade was a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 67,702 shares of company stock valued at $16,730,269. Company insiders own 0.88% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on DGX. UBS Group restated a “neutral” rating and set a $250.00 target price on shares of Quest Diagnostics in a research report on Monday, October 19th. Argus set a $260.00 price target on Quest Diagnostics in a report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price target on Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a report on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating and set a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. Finally, Mizuho boosted their price objective on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $248.70.

Read Our Latest Report on DGX

Quest Diagnostics Stock Performance

Quest Diagnostics stock opened at $259.46 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.58 and a current ratio of 1.70. The company has a market capitalization of $28.55 billion, a PE ratio of 25.84, a P/E/G ratio of 2.32 and a beta of 0.54. The company has a 50 day moving average price of $241.23 and a 200-day moving average price of $215.58. Quest Diagnostics Incorporated has a fifty-two week low of $171.18 and a fifty-two week high of $262.00.

Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its quarterly earnings data on Thursday, October 22nd. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.87 by $0.13. The company had revenue of $3.10 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. Quest Diagnostics’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.60 earnings per share. As a group, equities analysts forecast that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 27th. Stockholders of record on Tuesday, January 12th will be given a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, January 12th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.3%. Quest Diagnostics’s dividend payout ratio is presently 34.26%.

Quest Diagnostics Company Profile

(Free Report)

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.

Featured Stories

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.